Abstract
To compare the effects of different therapy regimens on the probability of emergence of new resistant mutants during therapy. We developed a stochastic model of infection and treatment to calculate the probability of de novo resistance during therapy. We simulated diverse treatment regimens, with different efficacy in controlling HIV replication. We studied the use of genotypic testing to choose treatment protocols specifically tailored against the wild type. The probability of emergence of a previously nonexisting drug-resistant mutant during therapy depends crucially on the drug regimen used. In particular, therapy protocols targeting the wild-type strain may lead to a higher probability of treatment failure due to resistance. Conversely, targeting the minority strains in the population, which readily mutate into the resistant variety, significantly lowers the probability of a new resistant emerging under therapy. Use of genotypic testing may lead to wrong decisions in the choice of therapy if the population dynamics of production of new resistant mutants is not taken into account.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of acquired immune deficiency syndromes (1999)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
